Science & Evidence
The Evidence Base for Pharmaceutical Cannabis
HMF Research’s five foundational research pillars are grounded in the existing scientific literature. We curate the evidence relevant to our production methodology, cannabinoid science, and regulatory pathway development.
5
Research Pillars
Ghana
West Africa Based Research
GACP
Compliant Methodology
Peer
Reviewed Evidence Base
Key Publication
The Scientific Case for Ghana Pharmaceutical Cannabis
Peer-reviewed research validates the potential for pharmaceutical-grade medicinal cannabis production in Ghana — grounding HMF Ltd’s operational framework in published evidence.
Journal of Cannabis Research · 2025
Medicinal Hemp Production in Ghana: Regulatory Framework, Agronomic Potential, and Pharmaceutical Quality Pathways
This peer-reviewed study examines Ghana’s legislative and agronomic foundations for pharmaceutical-grade medicinal hemp production, assessing the NACOC regulatory pathway, soil and climate suitability, and the phytochemical profile of Ghanaian hemp cultivars.
Key findings confirm Ghana’s equatorial climate supports year-round hemp cultivation with cannabinoid profiles suitable for pharmaceutical applications — and that the NACOC regulatory framework provides a viable pathway to international compliance standards.
“Ghana’s amended Narcotic Control Commission Act creates a viable legal framework for pharmaceutical-grade cannabis cultivation, with agronomic conditions that compare favourably to established production regions in Europe and Canada.”
Journal of Cannabis Research · 2025 · Medicinal Hemp in Ghana
Research Framework
Five Foundational Research Pillars
HMF Research’s scientific programme is structured around five pillars that connect production practice to the evidence base for pharmaceutical cannabis.
01
Cannabinoid Profile & Concentration
Developing stable, reproducible cannabinoid and terpene profiles through validated HPLC analytical methodologies. Evidence base spans characterisation studies for THC, CBD, CBG, CBC, and minor cannabinoids relevant to pharmaceutical formulation.
02
Genetics & Phenotype Stabilisation
Long-term breeding and phenotype tracking programmes focused on pharmaceutical consistency. Drawing on established principles in plant phenotype stability and the emerging evidence base for cannabis chemotype inheritance.
03
Cultivation Science (GACP Optimisation)
Controlled-environment and open-field trials optimising yield, potency, and contaminant control. Research informed by the WHO GACP guidelines for medicinal plants and Ghana-specific agronomic studies.
04
Post-Harvest & Pharmaceutical Processing
Drying, curing, extraction-readiness, and EU-GMP-aligned quality control frameworks. Evidence base draws on pharmaceutical degradation studies for cannabinoids and Ph. Eur. monograph developments for cannabis flower.
05
Regulatory & Clinical Development Pathways
Building the foundation for pre-clinical collaboration and international regulatory submission readiness. Research encompasses EMEA framework for cannabis-based medicines, Schedule I variation pathways, and African regulatory harmonisation developments under AUDA-NEPAD.
Evidence Library
Key Published Research Relevant to Our Work
HMF Research curates the peer-reviewed evidence base most directly relevant to our production methodology and pharmaceutical market context. These are independent publications — not funded by HMF Ltd.
West Africa
Medicinal Hemp in Ghana: Agronomic Potential and Regulatory Pathway Assessment
Multiple authors · Ghana research institutions
Journal of Cannabis Research · 2025
Comprehensive assessment of Ghana’s NACOC regulatory framework, soil and climate suitability, and phytochemical profiles of Ghanaian hemp cultivars for pharmaceutical applications.
GACP
WHO Guidelines on Good Agricultural and Collection Practices (GACP) for Medicinal Plants
World Health Organization
WHO Publications · 2003, updated guidance 2022
The foundational document for GACP implementation across medicinal plant production globally. HMF Ltd’s GACP framework is built directly from this guidance and its pharmaceutical cannabis-specific extensions.
Clinical
Medicinal Cannabis: Evidence Review for Pain, Nausea, and Neurological Applications
Multiple systematic reviews · Cochrane, NICE
Cochrane Library / NICE Evidence Review · 2023–2025
Systematic reviews of the clinical evidence for cannabis-based medicines in pain management, chemotherapy-induced nausea, and neurological conditions — establishing the therapeutic applications that drive pharmaceutical demand.
Chemistry
Cannabinoid Stability in Pharmaceutical-Grade Dried Cannabis: Degradation Pathways and Storage Parameters
Multiple authors · European pharmaceutical research
Journal of Pharmaceutical Sciences · 2024
Critical degradation pathway data for THC, CBD, and minor cannabinoids under varying temperature, humidity, and light conditions — informing HMF Ltd’s packaging and storage specifications.
Regulatory
European Monitoring Centre for Drugs and Drug Addiction: Medical Use of Cannabis and Cannabinoids — Questions and Answers for Policymakers and Health Authorities
EMCDDA
EMCDDA Publications · 2018, updated 2023
Framework document for EU pharmaceutical cannabis policy, covering regulatory status by member state, import authorisation requirements, and quality standards for medicinal cannabis products.
West Africa
Cannabis Policy Reform in Sub-Saharan Africa: Regulatory Frameworks and Economic Opportunities
Multiple authors · African policy research
International Journal of Drug Policy · 2024
Comparative analysis of cannabis regulatory reform across Sub-Saharan Africa, with specific coverage of Ghana’s NACOC framework as a model for pharmaceutical-grade production licensing.
HMF White Papers
Our Own Scientific Position Documents
Summaries of HMF Research’s position on key topics — written for pharmaceutical partners and regulatory stakeholders. Full documents available via Document Library.
Cannabinoid Stability in Pharmaceutical-Grade Dried Cannabis: Degradation Pathways and Storage Parameters
HMF Research · White Paper · 2026 · 8 pages
Cannabinoid Profile Consistency: Methodology for Batch-to-Batch Pharmaceutical Standardisation
HMF Research · Technical Brief · 2026 · 5 pages
Ghana’s LI 2475: Regulatory Compliance Requirements for Pharmaceutical Cannabis Export
HMF Research · Regulatory Summary · 2026 · 6 pages
The Case for African-Origin Pharmaceutical Cannabis: Cost, Quality, and Supply Chain Analysis
HMF Research · Market Analysis · 2025 · 10 pages
Scientific Collaboration Welcome
HMF Research works with academic institutions, CROs, and pharmaceutical R&D teams on cannabis science with direct relevance to pharmaceutical supply.